
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BMP-8A CRISPR/Cas9 KO Plasmid (h) | sc-406589 | 20 µg | $397.00 |
BMP8A encodes bone morphogenetic protein 8A (BMP-8A), a secreted ligand in the TGF-β superfamily that signals through BMP receptors to activate SMAD1/5/9-dependent transcriptional programs. BMP-8A contributes to regulation of developmental patterning, tissue differentiation, and remodeling, and can influence cellular processes such as proliferation, lineage commitment, and extracellular matrix dynamics. As part of the broader BMP signaling network, BMP8A intersects with pathways that govern morphogenesis and organogenesis and can modulate crosstalk with MAPK and other context-specific signaling cascades. Dysregulated BMP pathway activity, including altered ligand availability, is associated with aberrant developmental phenotypes and has been studied in disease-relevant contexts involving fibrosis, skeletal biology, and tumor microenvironment signaling.
BMP-8A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BMP8A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BMP8A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BMP8A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BMP-8A protein expression.
This CRISPR knockout system enables efficient generation of BMP8A-deficient cell models for investigation of BMP-8A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.